... killer cells could be significantly (at least 2-fold) enhanced when rIL-2- induced effector cells were preincubated for 18 h in the presence of recombinant Interferon-α rIFN-α; 1,000 U/ml). In summary, our results indicate the potential antitumor efficacy of rIL2- and rIL2 + rlFN-α-activated killer cells...

... low-dose recombinant interleukin-2 (rIL-2) and recombinant interferon-α (rIFN-α) as subcutaneous home therapy. A total of 31 patients with progressive metastatic renal cell carcinoma, malignant melanoma, colorectal cancer, B-cell lymphoma, and Hodg-kin’s disease, were evaluated. Patients were treated...

...B. Dreno; P. Celerier; P. Litoux In cutaneous T-cell lymphomas (CTCL; mycosis fungoides and Sézary syndrome), the standard therapies tend to be effective but not curative. Single drug therapy with either interferon-α or retinoids shows a response rate of about 45%. In this article, we report...

... therapy schedules via subcutaneous (s.c.) injection, mostly in combination with recombinant human interferon-α (rIFN-α). There were no significant differences in reported response rates between i.v. and s.c. treatment regimens. Methods. We retrospectively evaluated 148 treatment cycles of s.c...

... after 3 years. Complete remission was achieved with interferon-α (IFN-α) treatment following a previous combination of anticancer drugs. IFN-α was also effective for maintenance therapy after this complete, albeit transient, remission. From clinical and pathological studies on AILD patients, it appears...

...W. Verbeek; H. König; J. Boehm; D. Kohl; C. Lange; T. Heuer; C. Scheibenbogen; H.-E. Reis; A. Hochhaus; U. Graeven Interferon-α has been used as standard therapy for patients with Philadelphia-positive chronic myeloid leukemia (CML) for more than 20 years. Recently randomized trials have shown...

... (chronic phase) and treated with interferon-α for 13 years, developed renal failure. Renal biopsy showed thrombotic thrombocytopenic purpura, but intensive therapy including plasma exchange and steroid administration was not effective. The activity of von Willebrand factor-cleaving protease was detectable...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Adverse effects Autoimmune thrombocytopenia Chronic myelogenous leukemia Interferon-α Thrombocytopenia Few reports have described...

... peripheral blood stem cell transplantation Cytotoxic T lymphocytes Interferon-α Adult T cell leukemia/lymphoma (ATLL) is related to human T lymphotropic virus type 1 infection (HTLV-1) [ 1, 2 ]and is refractory to conventional chemotherapies [ 3, 4 ]. A recent study suggested that high...

... with a primary form of PCL treated with VAD combination achieving an objective response, and who received high-dose melphalan and autologous peripheral blood stem cell (PBSC) transplantation followed by interferon-α. During the remission time, lasting for 3 years, an infiltration by large granular lymphocytes...

... reported on the clinical effects of interferon-α (IFN-α) or the combination of 5-FU plus IFN-α on patients with advanced colorectal carcinoma. Therefore, we examined the ability of a retrovirus-mediated IFN-α gene transfer to infect colon cancer cells COLO 201 and the effect of IFN-α gene expression alone...

...) with a ‘maturation arrest’ at the level of pronormoblast. The patient has been transfusion-dependent for 8 months. Following diagnosis of chronic active hepatitis due to hepatitis C virus (HCV), therapy with interferon-α was initiated. Two weeks later, the hemoglobin level stabilized, and he has not required any...